Elucidating causes of vaginal symptoms using a multi-omics approach - Admin. Supplement

使用多组学方法阐明阴道症状的原因 - 管理员。

基本信息

  • 批准号:
    10091585
  • 负责人:
  • 金额:
    $ 9.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-05-13 至 2021-02-28
  • 项目状态:
    已结题

项目摘要

SUMMARY Transgender (trans) individuals are those who have a gender identity that does not match their birth-assigned sex. About 1.4 million adults in the United States identified as transgender in 2016. Trans people may take gender-affirming hormones or have undergone gender-affirming genital surgery. Little is known about approaches to sexual health screening and management, as well as risk for acquisition of sexually transmitted infections or development of other genital pathologies, in this population. The NIH has thus identified a major need for innovative research addressing the medical, sociological, psychological and structural causes and consequences of transgender and gender nonconforming identities. About ¼ of trans women (people assigned male at birth but with a female gender identity) have undergone vaginoplasty (surgical creation of a neovagina, typically using penile and scrotal skin) and while symptoms, such as malodor, discharge and irritation are commonly reported, little is known about the underlying pathophysiology. The vaginal microbiome in cis women is a critical determinant of health, yet our understanding of the composition and role of microbiota colonizing the neovagina is scarce and completely lacking for immune outcomes. In trans men, vaginectomy is rare (<2%), however an estimated 69% use gender-affirming testosterone therapy. Masculinizing hormone therapy has significant effects on the vaginal epithelium that result in reduced cellular proliferation and glycogen production. This is similar to vaginal atrophy observed during menopause in cis women, which affects the vaginal microbiota and has negative impacts on sexual health and quality of life. Little information is available on the relationship between vaginal microbiota and inflammation and the development of vaginal atrophy and symptoms in trans men. Given these unknowns, the short-term goals of this research are to better understand the causes of genital symptoms and the impact of these symptoms on sexual health and quality of life in trans women and men. We will achieve these goals establishing the TransBiota study and characterizing the immunological and microbiological vaginal microenvironments in trans women and men (Aim 1) and then testing for correlations between the vaginal microenvironment and patient characteristics, including sexual behaviors and hygiene practices (vaginal exposures), and importantly vaginal symptoms (Aim 2). We will implement an innovative home-based sampling strategy and an innovative statistical strategy that affords scientific rigor by correcting for experimental errors associated with microbiome analyses. Understanding the vaginal microenvironment and its role in sexual health in trans women and men is an important prerequisite to the development of clinical best- practices, which are currently lacking. The long-term goals of this study are to improve vaginal care for trans women and men and to ultimately leverage this information for the development of novel interventions to achieve optimal vaginal health and protection.
总结 跨性别者(Transgender)是指那些性别认同与其出生时的性别不匹配的人。 性2016年,美国约有140万成年人被认定为变性人。跨性别者可能会 或接受过性别确认生殖器手术。知之甚少 性健康检查和管理的方法,以及获得性传播疾病的风险 感染或其他生殖器疾病的发展。因此,NIH确定了一个主要的 需要进行创新研究,解决医学、社会学、心理学和结构性原因, 跨性别和性别认同的后果。大约1/4的跨性别女性(被分配到 出生时为男性但具有女性性别特征)进行了阴道成形术(手术产生新阴道, 典型地使用阴茎和阴囊皮肤),而诸如恶臭、分泌物和刺激的症状, 通常报道,很少有人知道的基本病理生理学。cis女性的阴道微生物组 是健康的关键决定因素,但我们对微生物群落的组成和作用的理解, 新生阴道是罕见的,完全缺乏免疫结果。在跨性别男性中,阴道切除术很少见(<2%), 然而,估计有69%的人使用性别肯定睾酮治疗。男性化激素疗法 对阴道上皮产生显著影响,导致细胞增殖和糖原产生减少。 这与在cis妇女绝经期观察到的阴道萎缩相似,这会影响阴道微生物群 并对性健康和生活质量产生负面影响。关于这种关系的信息很少 阴道微生物群和炎症与阴道萎缩和症状的发展之间的关系, 男人鉴于这些未知因素,本研究的短期目标是更好地了解生殖器疾病的原因。 症状以及这些症状对跨性别女性和男性性健康和生活质量的影响。我们 将实现这些目标,建立TransBiota研究并表征免疫和 跨性别女性和男性的阴道微环境(目标1),然后测试相关性 阴道微环境与患者特征(包括性行为和卫生习惯)之间的关系 实践(阴道暴露),以及重要的阴道症状(目标2)。我们将实施创新的 以家庭为基础的抽样策略和创新的统计策略,通过纠正 与微生物组分析相关的实验误差。了解阴道微环境及其 在跨性别女性和男性的性健康中的作用是临床最佳发展的重要前提, 目前缺乏的做法。这项研究的长期目标是改善阴道护理的反式 妇女和男子,并最终利用这一信息的发展新的干预措施,以实现 最佳的阴道健康和保护。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Towards a deeper understanding of the vaginal microbiota.
  • DOI:
    10.1038/s41564-022-01083-2
  • 发表时间:
    2022-03
  • 期刊:
  • 影响因子:
    28.3
  • 作者:
    France M;Alizadeh M;Brown S;Ma B;Ravel J
  • 通讯作者:
    Ravel J
High-resolution functional description of vaginal microbiomes in health and disease.
阴道微生物组在健康和疾病中的高分辨率功能描述。
  • DOI:
    10.1101/2023.03.24.533147
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Holm,JohannaB;France,MichaelT;Gajer,Pawel;Ma,Bing;Brotman,RebeccaM;Shardell,Michelle;Forney,Larry;Ravel,Jacques
  • 通讯作者:
    Ravel,Jacques
Cigarette smoking is associated with an altered vaginal tract metabolomic profile.
  • DOI:
    10.1038/s41598-017-14943-3
  • 发表时间:
    2018-01-16
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Nelson TM;Borgogna JC;Michalek RD;Roberts DW;Rath JM;Glover ED;Ravel J;Shardell MD;Yeoman CJ;Brotman RM
  • 通讯作者:
    Brotman RM
Complete Genome Sequence of Lactobacillus crispatus CO3MRSI1.
卷曲乳杆菌 CO3MRSI1 的完整基因组序列。
  • DOI:
    10.1128/mra.01538-18
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0.8
  • 作者:
    McComb,Elias;Holm,Johanna;Ma,Bing;Ravel,Jacques
  • 通讯作者:
    Ravel,Jacques
The Effect of Gender-Affirming Medical Care on the Vaginal and Neovaginal Microbiomes of Transgender and Gender-Diverse People.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LARRY J FORNEY其他文献

LARRY J FORNEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LARRY J FORNEY', 18)}}的其他基金

Host-Microbiota Interactions and Chlamydia Trachomatis Infection Outcomes
宿主-微生物群相互作用和沙眼衣原体感染结果
  • 批准号:
    10239625
  • 财政年份:
    2021
  • 资助金额:
    $ 9.99万
  • 项目类别:
Host-Microbiota Interactions and Chlamydia Trachomatis Infection Outcomes
宿主-微生物群相互作用和沙眼衣原体感染结果
  • 批准号:
    10449336
  • 财政年份:
    2021
  • 资助金额:
    $ 9.99万
  • 项目类别:
Elucidating causes of vaginal symptoms using a multi-omics approach
使用多组学方法阐明阴道症状的原因
  • 批准号:
    9883844
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
Elucidating causes of vaginal symptoms using a multi-omics approach
使用多组学方法阐明阴道症状的原因
  • 批准号:
    9273625
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
Development of the vaginal microbiome in young Black women
年轻黑人女性阴道微生物组的发育
  • 批准号:
    8898465
  • 财政年份:
    2014
  • 资助金额:
    $ 9.99万
  • 项目类别:
COBRE Phase III: Transitional Center for Research on Processes in Evolution
COBRE 第三阶段:进化过程研究过渡中心
  • 批准号:
    8796191
  • 财政年份:
    2013
  • 资助金额:
    $ 9.99万
  • 项目类别:
COBRE Phase III: Transitional Center for Research on Processes in Evolution
COBRE 第三阶段:进化过程研究过渡中心
  • 批准号:
    8304605
  • 财政年份:
    2013
  • 资助金额:
    $ 9.99万
  • 项目类别:
COBRE Phase III: Transitional Center for Research on Processes in Evolution
COBRE 第三阶段:进化过程研究过渡中心
  • 批准号:
    9213373
  • 财政年份:
    2013
  • 资助金额:
    $ 9.99万
  • 项目类别:
COBRE: UID: PROGRAM ADMINISTRATION & FACULTY MENTORING
COBRE:UID:项目管理
  • 批准号:
    8359575
  • 财政年份:
    2011
  • 资助金额:
    $ 9.99万
  • 项目类别:
COBRE: UID: DNA SEQUENCE ANALYSIS CORE FACILITY
COBRE:UID:DNA 序列分析核心设施
  • 批准号:
    8359573
  • 财政年份:
    2011
  • 资助金额:
    $ 9.99万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了